

澳大利亚生物技术协会 澳大利亚医疗技术公司名录



公司介绍

公司名称: Cardiac Dimensions Pty Ltd

主要联系人姓名: Jari Hyvarinen

主要联系人职务: 澳洲业务负责人

公司网址: www.cardiacdimensions.com

公司地址: Level 8, 15 Talavera Rd, Macquarie Park NSW 2113

公司未上市

公司简介

Cardiac Dimensions (CDI) 总部位于澳大利亚悉尼和美国华盛顿州柯克兰。CDI 是一家医疗设备公司，致力于开发和商品化新型非手术装置“Carillon”，专用于治疗功能性二尖瓣闭锁不全所引起的相关病症及心脏衰竭。CDI 已获得监管部门批准于欧洲上市销售此装置，且在德国多达 120 家医院中，使用该装置及接受疗程的花费皆可全额报销。

CDI 已于美国、德国、沙特阿拉伯完成了非盲人体试验，并符合德国、土耳其、沙特阿拉伯必要的监管协定和报销要求，透过临床医师进行销售。CDI 正向包含澳大利亚在内多个国家的监管部门申请产品上市批准。

关键技术或领先技术

CDI 致力于开发和销售名为“Carillon”的新型非手术装置，专用于治疗功能性二尖瓣闭锁不全所引起的相关病症以及心脏衰竭，治疗法以导管作为基础，以重塑二尖瓣并减低血液反流情况。由于装置易于植入（在局部麻醉情况下，只需约 1 小时就可完成）、与患者有良好的适应性和治疗效果（长达两年），此装置在临床使用获得极高的好评。与 MitraClip 相比（目前的通用治疗标准装置，该技术需要全身麻醉且植入过程可能超过 6 小时），三分之一的临床医师选择使用 Carillon。且基于实际使用案例，这些临床医师相信 Carillon 将成为治疗方案的首选。

类别

设备类: 心脏科

关键技术或领先技术的发展阶段

产品已经上市

合作机会

公司为进入美国市场和进一步开拓欧洲、亚洲市场，正寻求合作伙伴协助以开展临床测试。

Directory of Australian medtech companies



COMPANY DETAILS

Company name: Cardiac Dimensions Pty Ltd

Key contact name: Jari Hyvarinen

Job title of key contact: Head of Australian operations

Company website address: www.cardiacdimensions.com

Company address: Level 8, 15 Talavera Rd, Macquarie Park NSW 2113

The company is Unlisted.

ABOUT THE COMPANY

Cardiac Dimensions (CDI) is based in Sydney, Australia and Kirkland WA, USA. CDI is a medical device company that has been developing and commercialising a novel, non-surgical device (the “Carillon”) for the treatment of heart failure and specifically the related condition of functional mitral valve regurgitation. The Company has regulatory approval to sell their device in Europe, and the procedure and device are fully reimbursed in 120 hospitals in Germany

CDI completed non-blinded human trials in the US, Germany and Saudi Arabia and the device is currently being sold by clinicians in Germany, Turkey and Saudi Arabia where the necessary regulatory protocols and reimbursement requirements have already been met. The company is currently in the process of gaining regulatory approval in several other countries including Australia.

KEY OR LEAD TECHNOLOGY

CDI has been developing and commercialising a novel, non-surgical device called the “Carillon”. It is used for the treatment of heart failure and specifically the related condition of functional mitral valve regurgitation (“MR”), using a catheter-based approach to reshape the mitral valve and reduce regurgitation. Clinician feedback has been incredibly positive due to the ease of device implantation (the device can be implanted in around an hour under local anaesthetic), patient compatibility and patient results (up to two years). The Carillon is being implanted by these clinicians in the ratio of 1:2 compared to the MitraClip (current gold standard, which requires general anaesthetic and can be a 6hr+ procedure), and they expect the Carillon to become the preferred solution based on use cases.

Category

Devices: Cardiology

Point of development of key or lead technology

Product on the market

OPPORTUNITIES SOUGHT

The Company is seeking strategic partners to help with carrying out clinical studies, for US market entry and for current EU and Asian commercial efforts.